Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas(352 views) Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, Merola B, Salvatore M, Lombardi G
Affiliations: Dept. Molec. Clin. Endocrinol. O., Federico II University, 080131 Naples, Italy
Department of Nuclear Medicine, National Cancer Institute, Fondazione G. Pascale, 080131 Naples, Italy
CNR, 080131 Naples, Italy
Melmed, S., Ho, K., Klibanski, A., Reichlin, S., Thorner, M., Recent advances in pathology, diagnosis and management of acromegaly (1995) J Clin Endocrinol Metab., 80, pp. 3395-3402
Colao, A., Ferone, D., Marzullo, P., Effect of different dopaminergic agents in the treatment of acromegaly (1997) J Clin Endocrinol Metab., 82, pp. 518-523
Yamada, S., Asa, S.L., Kovaks, K., Muller, P., Smyth, H.S., Analysis of hormone secretion by clinically nonfunctioning human pituitary adenomas using the reverse hemolytic plaque assay (1989) J Clin Endocrinol Metab., 68, pp. 73-80
Saccomanno, K., Gil-del-Alamo, P., Bassetti, M., Reza-Elahi, F., Spada, A., In vitro detection of glycoprotein production and secretion by human nonfunctioning pituitary adenomas (1993) J Endocrinol Invest., 16, pp. 109-115
Closse, A., Cramps, M., Wanner, A., Palacios, J.M., In vivo labelling of brain dopamine D2 receptors using the high-affinity specific D2 agonist (3H)CV 205-502 (1988) Brain Res., 440, pp. 123-128
Brue, T., Pellegrini, I., Gunz, G., Effects of dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine (1992) J Clin Endocrinol Metab., 74, pp. 577-584
Colao, A., Merola, B., Sarnacchiaro, F., Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas (1995) Horm Res., 44, pp. 222-228
Chiodini, P.G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Lombardi, G., Colao, A., Ferone, D., CV 205-502 treatment in therapy-resistant acromegalic patients (1995) Eur J Endocrinol., 132, pp. 559-564
Kwekkeboom, D.J., Lamberts, S.W.J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Brücke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W.W., Reijs, A.E.M., Kwekkeboom, D.J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Scillitani, A., Dicembrino, F., Di Fazio, P., In vivo visualization of pituitary dopaminergic receptors by iodine-123 methoxybenzamide (IBZM) correlates with sensitivity to dopamine agonists in two patients with macroprolactinomas (1995) J Clin Endocrinol Metab., 80, pp. 2523-2525
Verhoeff, N.P., Bemelman, F.J., Wiersinga, W.M., Van Royen, E.A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N.P., Van Royen, E.A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M.J., Quast, L.M., Laws, E.R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P.E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M.D., Shalet, S.M., Beardwell, C.G., Ahmed, S.R., Applegate, G., Sutton, M.I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
Warnet, A., Timsit, J., Chanson, P., The effect of somatostatin analogue on chiasmal dysfunction from pituitary macroadenomas (1989) J Neurosurg., 71, pp. 687-690
De Bruin, T.W.A., Kwekkeboom, D.J., Van't Verlaat, J.W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Merola, B., Colao, A., Ferone, D., Effects of chronic treatment with octreotide in patients with functionless pituitary adenomas (1993) Horm Res., 40, pp. 149-155
Plöckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H.J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J.S., Burke, C.W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
Koga, M., Nakao, H., Arao, M., Demonstration of specific dopamine receptors on human pituitary adenomas (1987) Acta Endocrinol, 114, pp. 595-602. , Copenh
De Herder, W.W., Lamberts, S.W.J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W.D., Abrams, D.N., Greenberg, C.R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Riedl, M., Luger, A., Dopamine D2 receptor imaging in pituitary adenomas using iodine-123-epidepride and SPECT (1996) J Nucl Med., 37, pp. 1931-1937
Pirker, W., Brücke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
Bevan, J. S., Webster, J., Burke, C. W., Scanlon, M. F., Dopamine agonists and pituitary tumor shrinkage (1992) Endocr Rev., 13, pp. 220-24
Chiodini, P. G., Attanasio, R., Cozzi, R., CV 205-502 in acromegaly (1993) Acta Endocrinol, 128, pp. 389-393. , Copenh
Kwekkeboom, D. J., Lamberts, S. W. J., Long-term treatment with dopamine agonist CV 205-502 of patients with clinically non-functioning, gonadotroph, or -subunit secreting pituitary adenoma (1992) Clin Endocrinol, 36, pp. 171-176. , Oxf
Br cke, T., Wenger, S., Asenbaum, S., Dopamine D2 receptor imaging and measurements with SPECT (1993) Adv Neurol., 60, pp. 494-500
De Herder, W. W., Reijs, A. E. M., Kwekkeboom, D. J., In vivo imaging of pituitary tumors using a radiolabeled dopamine D2 receptor radioligand (1996) Clin Endocrinol, 45, pp. 755-767. , Oxf
Verhoeff, N. P., Bemelman, F. J., Wiersinga, W. M., Van Royen, E. A., Imaging of dopamine D2 and somatostatin receptors in vivo using single-photon emission tomography in a patient with TSH/PRL-producing pituitary macroadenoma (1993) Eur J Nucl Med., 20, pp. 555-561
Verhoeff, N. P., Van Royen, E. A., Van Royen, N., Dopamine D2-receptor imaging with dynamic I-123 iodo benzamide SPECT in healthy human volunteers (1991) J Nucl Med., 32, pp. 1076-1079
Ebersold, M. J., Quast, L. M., Laws, E. R., Long-term results in transsphenoidal removal of nonfunctioning pituitary adenomas (1986) J Neurosurg., 334, pp. 246-254
Harris, P. E., Afshar, F., Coates, P., The effects of transsphenoidal surgery on endocrine function and visual fields in patients with functionless pituitary adenomas (1989) Q J Med New Series, 71, p. 417
Littley, M. D., Shalet, S. M., Beardwell, C. G., Ahmed, S. R., Applegate, G., Sutton, M. I., Hypopituitarism following external radiotherapy for pituitary tumors in adults (1989) Q J Med New Series, 70, p. 145
De Bruin, T. W. A., Kwekkeboom, D. J., Van't Verlaat, J. W., Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro (1992) J Clin Endocrinol Metab., 75, pp. 1310-1317
Pl ckinger, U., Reichel, M., Fett, U., Saeger, W., Quabbe, H. J., Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: Effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy (1994) J Clin Endocrinol Metab., 79, pp. 1416-1423
Bevan, J. S., Burke, C. W., Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine (1986) Clin Endocrinol, 25, pp. 561-572. , Oxf
De Herder, W. W., Lamberts, S. W. J., Imaging of pituitary tumours (1995) Baillieres Clin Endocrinol Metab., 9, pp. 367-389
Leslie, W. D., Abrams, D. N., Greenberg, C. R., Hobson, D., Comparison of iodine-123-epidepride and iodine-123-IBZM for dopamine D2 receptor imaging (1996) J Nucl Med., 37, pp. 1589-1591
Pirker, W., Br cke, T., Riedl, M., Iodine-123-IBZM-SPECT: Studies in 15 patients with pituitary tumors (1994) J Neural Transm., 97, pp. 235-244
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
The efficacy of dopaminergic agents in the medical treatment of pituitary adenomas is well known. Quinagolide is a nonergot derivative dopamine agonist, which binds dopamine D2 receptors with high affinity. The treatment with this drug is reported to suppress hormone levels and to cause tumor shrinkage in prolactinomas and in a few GH-secreting pituitary adenomas. In clinically nonfunctioning pituitary adenomas (NFPA), the efficacy of quinagolide treatment is controversial. The scintigraphy of the pituitary region using 123-Imethoxybenzamide (123I-IBZM) allows us to visualize in vivo the expression of dopamine D2 receptors on pituitary tumors. In this study, the pituitary scintigraphy with 123I-IBZM was performed in 14 patients with macroadenoma before starting a long-term treatment with quinagolide: 6 NFPA with high circulating α-subunit levels, 4 PRL-secreting, and 4 GH-secreting adenomas. A 3-point score was used to grade the ligand accumulation within the pituitary adenomas: 0 = negative, 1 = moderate uptake (equal to that recorded in the cerebral cortex), and 2 = intense uptake (equal to that recorded in the basal nuclei). The treatment with quinagolide was carried out at the dose of 0.3-0.6 mg/day for 6-12 months. Clinical, biochemical and hormonal assessment was repeated monthly during the first 3 months, then quarterly. Sellar magnetic resonance imaging was per- formed before and after 6 and 12 months of quinagolide treatment, to evaluate tumor shrinkage (>25% of baseline size). In all 14 patients, a significant positive correlation was found between the degree of 123I- IBZM uptake and the clinical response to quinagolide treatment (r = 0.90; P < 0.001). In particular, the normalization of serum α-subunit and PRL levels, respectively, was achieved in 3 patients with NFPA and in 2 patients with prolactinoma, who showed intense 123I-IBZM uptake in the pituitary region. In 4 of these 5 patients with positive scan, a significant tumor shrinkage occurred between 6 and 12 months after the beginning of quinagolide treatment. In all patients with GH-secreting adenoma, no significant uptake of 123I-IBZM was found and no significant decrease of circulating GH and/or insulin-like growth factor-I levels, and tumor shrinkage was obtained during long-term treatment with quinagolide. In conclusion, the pituitary scintigraphy with 123I-IBZM can be considered a useful tool to indicate adenomas with significant expression of functioning D2 receptors. This innovative technique may predict the response to long-term treatment with quinagolide in patients with NFPA, where the lack of pituitary hormone hypersecretion makes difficult the monitoring of medical treatment efficacy.
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas
Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas